{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:39:42Z","timestamp":1790739582765,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["102121\/C"],"award-info":[{"award-number":["102121\/C"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["SVV 260 663"],"award-info":[{"award-number":["SVV 260 663"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007543","name":"Grantov\u00e1 Agentura, Univerzita Karlova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bcp.2023.115769","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:11:19Z","timestamp":1692961879000},"page":"115769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo"],"prefix":"10.1016","volume":"216","author":[{"given":"Youssif","family":"Budagaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziba","family":"Sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Novotn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Hanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Rozko\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2023.115769_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: a Cancer J. Clinic."},{"issue":"1","key":"10.1016\/j.bcp.2023.115769_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12094-018-1978-1","article-title":"SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)","volume":"21","author":"Majem","year":"2019","journal-title":"Clin. Transl. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115769_b0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: a dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat. Rev. Genet."},{"issue":"7330","key":"10.1016\/j.bcp.2023.115769_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2023.115769_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-021-01069-7","article-title":"Advances in epigenetic therapeutics with focus on solid tumors","volume":"13","author":"Jin","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"1","key":"10.1016\/j.bcp.2023.115769_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00721-x","article-title":"Recent developments in epigenetic cancer therapeutics: Clinical advancement and emerging trends","volume":"28","author":"Nepali","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2023.115769_b0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.bcp.2023.115769_b0040","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bcp.2023.115769_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomarker Res."},{"key":"10.1016\/j.bcp.2023.115769_b0050","doi-asserted-by":"crossref","unstructured":"C. Behrens, L.M. Solis, H. Lin, P. Yuan, X. Tang, H. Kadara, E. Riquelme, H. Galindo, C.A. Moran, N. Kalhor, EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non\u2013Small Cell Lung CarcinomaEZH2 Expression in Non\u2013Small Cell Lung Carcinoma, Clin. Cancer Res. 19(23) (2013) 6556-6565.","DOI":"10.1158\/1078-0432.CCR-12-3946"},{"key":"10.1016\/j.bcp.2023.115769_b0055","first-page":"1","article-title":"EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization","author":"Gallardo","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2023.115769_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-021-01045-1","article-title":"Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors","volume":"13","author":"Li","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"2","key":"10.1016\/j.bcp.2023.115769_b0065","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s11033-021-06155-w","article-title":"ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine","volume":"48","author":"Juan-Carlos","year":"2021","journal-title":"Molecul. Biol. Report."},{"issue":"10","key":"10.1016\/j.bcp.2023.115769_b0070","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s12094-020-02325-7","article-title":"Drug-metabolizing enzymes: role in drug resistance in cancer","volume":"22","author":"Kaur","year":"2020","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bcp.2023.115769_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109448","article-title":"Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance","volume":"340","author":"Hofman","year":"2021","journal-title":"Chemico-Biol. Interact."},{"issue":"7","key":"10.1016\/j.bcp.2023.115769_b0080","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2023.115769_b0085","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Hee Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2023.115769_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bcp.2023.115769_b0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2023.115769_b0100","unstructured":"FDA, Food and Drug Administration. In Vitro Drug Interaction Studies \u2014Cytochrome P450 Enzyme-and Transporter-Mediated Drug Interactions Guidance for Industry, Clinical Pharmacology, Silver Spring, MD (2020)."},{"key":"10.1016\/j.bcp.2023.115769_b0105","unstructured":"EMA, European Medicines Agency, Guideline on the Investigation of Drug Interactions. CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2, European Medicines Agency London, UK, 2012."},{"key":"10.1016\/j.bcp.2023.115769_b0110","doi-asserted-by":"crossref","unstructured":"N.B. Elkind, Z. Szentp\u00e9tery, \u00c1. Ap\u00e1ti, C. Ozvegy-Laczka, G.r. V\u00e1rady, O. Ujhelly, K. Szab\u00f3, L. Homolya, A. V\u00e1radi, L. Buday, Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib), Cancer research 65(5) (2005) 1770-1777.","DOI":"10.1158\/0008-5472.CAN-04-3303"},{"key":"10.1016\/j.bcp.2023.115769_b0115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cbi.2015.10.009","article-title":"Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity","volume":"255","author":"Xuan","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2023.115769_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115009","article-title":"Sonidegib potentiates the cancer cells\u2019 sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo","volume":"199","author":"Zhang","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"21","key":"10.1016\/j.bcp.2023.115769_b0125","doi-asserted-by":"crossref","first-page":"11936","DOI":"10.3390\/ijms222111936","article-title":"Tepotinib inhibits several drug efflux transporters and biotransformation enzymes: the role in drug-drug interactions and targeting cytostatic resistance in vitro and ex vivo","volume":"22","author":"Vagiannis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115769_b0130","doi-asserted-by":"crossref","unstructured":"R. Wu Growth of human lung tumor cells in culture, Culture of Human Tumor Cells R. Pfragner R.I. Freshney Wiley-Liss Inc 2004 Hoboken, NJ 1 21.","DOI":"10.1002\/0471722782.ch1"},{"issue":"22","key":"10.1016\/j.bcp.2023.115769_b0135","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.3390\/ijms232214338","article-title":"Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study","volume":"23","author":"Sabet","year":"2022","journal-title":"Int. J. Molecul. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2023.115769_b0140","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J. Chem. Inf. Model."},{"issue":"8","key":"10.1016\/j.bcp.2023.115769_b0145","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1107\/S0907444904011679","article-title":"PRODRG: a tool for high-throughput crystallography of protein\u2013ligand complexes","volume":"60","author":"Sch\u00fcttelkopf","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"issue":"13","key":"10.1016\/j.bcp.2023.115769_b0150","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2023.115769_b0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bcp.2023.115769_b0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/molecules28020495","article-title":"A Structure-Based View on ABC-Transporter Linked to Multidrug Resistance","volume":"28","author":"Huang","year":"2023","journal-title":"Molecules"},{"issue":"W1","key":"10.1016\/j.bcp.2023.115769_b0165","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.bcp.2023.115769_b0170","doi-asserted-by":"crossref","first-page":"D313","DOI":"10.1093\/nar\/gkw1132","article-title":"The SWISS-MODEL Repository\u2014new features and functionality","volume":"45","author":"Bienert","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"S1","key":"10.1016\/j.bcp.2023.115769_b0175","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1002\/elps.200900140","article-title":"Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective","volume":"30","author":"Guex","year":"2009","journal-title":"Electrophoresis"},{"key":"10.1016\/j.bcp.2023.115769_b0180","unstructured":"UniProt: the Universal Protein knowledgebase in 2023, Nucleic Acids Research 51(D1) (2023) D523-D531."},{"key":"10.1016\/j.bcp.2023.115769_b0185","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.119.086975","article-title":"Interactions of alectinib with human ABC drug efflux transporters and CYP450 biotransformation enzymes: effect on pharmacokinetic multidrug resistance","author":"Hofman","year":"2019","journal-title":"Drug Metab. Dispos."},{"issue":"16","key":"10.1016\/j.bcp.2023.115769_b0190","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2023.115769_b0195","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2023.115769_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114061","article-title":"Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme","volume":"178","author":"Vagiannis","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115769_b0205","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/cancers12040813","article-title":"Ensartinib (X-396) effectively modulates pharmacokinetic resistance mediated by ABCB1 and ABCG2 drug efflux transporters and CYP3A4 biotransformation enzyme","volume":"12","author":"Vagiannis","year":"2020","journal-title":"Cancers"},{"issue":"W1","key":"10.1016\/j.bcp.2023.115769_b0210","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: expanding the scope of the protein\u2013ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.bcp.2023.115769_b0215","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2023.115769_b0220","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/ci400195v","article-title":"Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein","volume":"53","author":"Ferreira","year":"2013","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.bcp.2023.115769_b0225","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1021\/acs.jmedchem.1c01272","article-title":"Discovery and Characterization of Potent Dual P-Glycoprotein and CYP3A4 Inhibitors: Design, Synthesis, Cryo-EM Analysis, and Biological Evaluations","volume":"65","author":"Urgaonkar","year":"2021","journal-title":"J. Med. Chem."},{"issue":"42","key":"10.1016\/j.bcp.2023.115769_b0230","doi-asserted-by":"crossref","first-page":"26245","DOI":"10.1073\/pnas.2010264117","article-title":"Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1","volume":"117","author":"Nosol","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6428","key":"10.1016\/j.bcp.2023.115769_b0235","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.aav7102","article-title":"Structural insight into substrate and inhibitor discrimination by human P-glycoprotein","volume":"363","author":"Alam","year":"2019","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.bcp.2023.115769_b0240","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","article-title":"Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2","volume":"110","author":"Knutson","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2023.115769_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16155-2","article-title":"ABCG2 transports anticancer drugs via a closed-to-open switch","volume":"11","author":"Orlando","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2023.115769_b0250","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2017.01.041","article-title":"Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1","volume":"168","author":"Johnson","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.bcp.2023.115769_b0255","doi-asserted-by":"crossref","first-page":"10692","DOI":"10.1096\/fj.201900140R","article-title":"Structure-guided probing of the leukotriene C4 binding site in human multidrug resistance protein 1 (MRP1; ABCC1)","volume":"33","author":"Conseil","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2023.115769_b0260","article-title":"Overexpression of ABCC1 confers drug resistance to betulin","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2023.115769_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115769_b0270","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/JTO.0b013e318258cf17","article-title":"Gefitinib Enhances Cytotoxicities of Antimicrotubule Agents in Non\u2013Small-Cell Lung Cancer Cells Exhibiting No Sensitizing Epidermal Growth Factor Receptor Mutation","volume":"7","author":"Tsai","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115769_b0275","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jebm.12434","article-title":"ATP-binding cassette (ABC) transporters in cancer: A review of recent updates","volume":"14","author":"Wang","year":"2021","journal-title":"J. Evid. Based Med."},{"issue":"3","key":"10.1016\/j.bcp.2023.115769_b0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Szak\u00e1cs","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.bcp.2023.115769_b0285","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol."},{"issue":"23","key":"10.1016\/j.bcp.2023.115769_b0290","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115769_b0295","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biopha.2018.02.038","article-title":"Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR","volume":"100","author":"Mohammad","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.bcp.2023.115769_b0300","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/ijc.29566","article-title":"ABCB 1 and ABCG 2 restrict the brain penetration of a panel of novel EZH 2-Inhibitors","volume":"137","author":"Zhang","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2023.115769_b0305","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1124\/jpet.109.160564","article-title":"Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility","volume":"331","author":"Cygalova","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.bcp.2023.115769_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115823","article-title":"Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter","volume":"434","author":"Vagiannis","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115769_b0315","doi-asserted-by":"crossref","first-page":"e26218","DOI":"10.1002\/pbc.26218","article-title":"Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program","volume":"64","author":"Kurmasheva","year":"2017","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522300360X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000629522300360X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:46:28Z","timestamp":1757771188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000629522300360X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":63,"alternative-id":["S000629522300360X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115769","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115769","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115769"}}